Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

13.05
-1.4000-9.69%
Post-market: 13.05-0.0019-0.01%19:57 EDT
Volume:5.01M
Turnover:66.37M
Market Cap:3.37B
PE:3.92
High:14.25
Open:14.08
Low:13.00
Close:14.45
Loading ...

Why Organon (OGN) Could Beat Earnings Estimates Again

Zacks
·
03 Apr

Organon Acquires Tofidence for Intravenous Infusion in US

MT Newswires Live
·
01 Apr

Organon & Co - to Pay Tiered Royalties and Milestone Payments to Biogen

THOMSON REUTERS
·
01 Apr

Organon Acquires Tofidence™ (Tocilizumab-Bavi), a Commercialized Biosimilar to Actemra® (Tocilizumab) Injection, for Intravenous Infusion in the U.S.

THOMSON REUTERS
·
01 Apr

Organon & Co - Bio-Thera Solutions to Maintain Manufacturing Rights for Tofidence

THOMSON REUTERS
·
01 Apr

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

MT Newswires Live
·
28 Mar

BRIEF-European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11

Reuters
·
28 Mar

European Medicines Agency (Ema) Validates Henlius and Organon Filing for Perjeta® (Pertuzumab) Biosimilar Candidate Hlx11

THOMSON REUTERS
·
28 Mar

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire
·
28 Mar

Barclays Sticks to Its Buy Rating for Organon (OGN)

TIPRANKS
·
10 Mar

May Health Appoints Seasoned Medtech Executive, Colby Holtshouse, as President and CEO

THOMSON REUTERS
·
10 Mar

Organon announes results from analysis of Phase 3 ADORING 3 study

TIPRANKS
·
10 Mar

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire
·
08 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.
·
17 Feb

Organon & Co. Navigates Growth Amidst Challenges

TIPRANKS
·
17 Feb

Organon Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
15 Feb

Organon & Is Maintained at Overweight by Barclays

Dow Jones
·
14 Feb

Bank of America Securities Reaffirms Their Sell Rating on Organon (OGN)

TIPRANKS
·
14 Feb

Morgan Stanley Keeps Their Hold Rating on Organon (OGN)

TIPRANKS
·
14 Feb